Lifeboat Foundation

Scientists think they’ve identified a previously unknown form of neural communication that self-propagates across brain tissue, and can leap wirelessly from neurons in one section of brain tissue to another – even if they’ve been surgically severed.

The discovery offers some radical new insights about the way neurons might be talking to one another, via a mysterious process unrelated to conventionally understood mechanisms, such as synaptic transmission, axonal transport, and gap junction connections.

“We don’t know yet the ‘So what?’ part of this discovery entirely,” says neural and biomedical engineer Dominique Durand from Case Western Reserve University.

Continue reading “Neuroscientists Say They’ve Found an Entirely New Form of Neural Communication” »

The immune system is incredibly important, thanks to its role in fighting off dangerous invaders in our bodies. But sometimes it gets it wrong, targeting harmless proteins from things like nuts or dairy products and triggering allergic reactions that ironically can themselves be fatal. Now, researchers from Michigan State University have identified a mechanism that helps keep the immune system in check, potentially paving the way for drugs that could prevent allergic reactions before they start.

A toxic antibody is the latest weapon to show promise as a broad spectrum treatment for multiple forms of advanced cancer.

Dubbed a ‘Trojan horse’ approach to chemotherapy, the new drug has proven itself worthy of moving up the chain of clinical trials to being tested on a greater variety of patients. It’s not a fabled cure-all, but this approach might be as close as we’re going to get.

Researchers from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust tested the new treatment in a clinical trial involving 147 patients to evaluate its potential benefits and risks of side effects.

Continue reading “This New ‘Trojan Horse’ Drug Successfully Treated 6 Types of Cancer Tumor” »

SpaceX is building a steel launch system called Starship for the moon and Mars, but some aerospace experts say Elon Musk’s new design won’t be easy.

The genetic and cellular alterations that define cancer provide the immune system with the means to generate T cell responses that recognize and eradicate cancer cells. However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which manages the delicate balance between the recognition of nonself and the prevention of autoimmunity. Identification of cancer cell T cell inhibitory signals, including PD-L1, has prompted the development of a new class of cancer immunotherapy that specifically hinders immune effector inhibition, reinvigorating and potentially expanding preexisting anticancer immune responses. The presence of suppressive factors in the tumor microenvironment may explain the limited activity observed with previous immune-based therapies and why these therapies may be more effective in combination with agents that target other steps of the cycle. Emerging clinical data suggest that cancer immunotherapy is likely to become a key part of the clinical management of cancer.

Genetic, epidemiologic, and biochemical evidence suggests that predisposition to Alzheimer’s disease (AD) may arise from altered cholesterol metabolism, although the molecular pathways that may link cholesterol to AD phenotypes are only partially understood. Here, we perform a phenotypic screen for pTau accumulation in AD-patient iPSC-derived neurons and identify cholesteryl esters (CE), the storage product of excess cholesterol, as upstream regulators of Tau early during AD development. Using isogenic induced pluripotent stem cell (iPSC) lines carrying mutations in the cholesterol-binding domain of APP or APP null alleles, we found that while CE also regulate Aβ secretion, the effects of CE on Tau and Aβ are mediated independent pathways. Efficacy and toxicity screening in iPSC- derived astrocytes and neurons showed that allosteric activation of CYP46A1 lowers CE specifically in neurons and is well tolerated by astrocytes. These data reveal that CE independently regulate Tau and Aβ and identify a druggable CYP46A1-CE-Tau axis in AD.

Van der Kant et al. performed a repurposing drug screen in iPSC-derived AD neurons and identified compounds that reduce aberrant accumulation of phosphorylated Tau (pTau). Reduction of cholesteryl ester levels or allosteric activation of CYP46A1 by lead compounds enhanced pTau degradation independently of APP and Aβ.

Une belle avancée pour augmenter considérablement le nombre de greffons disponibles pour les transplantations!

Via Explore Science

Transmedics, a machine that allows “Revive” a heart that has stopped beating. A great advance to significantly increase the number of plugins available for transplants! Via @[1382701505100571:274:Explore Science].

The derivation of human embryonic stem cells (hESCs) and the stunning discovery that somatic cells can be reprogrammed into human induced pluripotent stem cells (hiPSCs) holds the promise to revolutionize biomedical research and regenerative medicine. In this Review, we focus on disorders of the central nervous system and explore how advances in human pluripotent stem cells (hPSCs) coincide with evolutions in genome engineering and genomic technologies to provide realistic opportunities to tackle some of the most devastating complex disorders.

Advances in stem cell biology are paving new paths toward their use in the clinic, especially toward understanding and treating neurological and neurodegenerative disease.

Harnessing an antitumor immune response has been a fundamental strategy in cancer immunotherapy. For over a century, efforts have primarily focused on amplifying immune activation mechanisms that are employed by humans to eliminate invaders such as viruses and bacteria. This “immune enhancement” strategy often results in rare objective responses and frequent immune-related adverse events (irAEs). However, in the last decade, cancer immunotherapies targeting the B7-H1/PD-1 pathway (anti-PD therapy), have achieved higher objective response rates in patients with much fewer irAEs.

This Perspective discusses the concept of immune normalization and how its underlying principles may help to augment, as well as design, cancer immunotherapies.